ARCHIVES

Scripps, Sandoz Deal Becomes Case Study As NI Rethinks Sponsored Research

This article is from The Cancer Letter archive.

Vol. 20 No. 04 | January 28, 1994

Download PDF Visit The Full Archive

Related Articles

In Brief: NCAB to Hear Program Review, Reports On AIDs Monoclonal Antibodies, Cancer Research at Drew

November 25, 1983

ASCO Annual Meeting Attendance Tops 25,000, Continuing Fast Growth.

May 18, 2001

Cancer Mmeetings Lister For Next Three Months

February 23, 1996

Phase 0 Trials Signal FDA’s New Reliance On Biomarkers For Drug Development.

January 13, 2006

Docetaxel, Oxaliplatin Active Against Esophageal Cancer

June 30, 2006

National Cancer Act Of 1971 Commemorated In Symposium Marking Progress, Future Goals

December 13, 1991